{
  "generated": "2025-11-06T07:07:41.113290+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/neurological/vinpocetine-cogn-gen-0140/cognition/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "COGN-GEN-0140_01",
      "year": 2012,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "focus",
      "population": "Adults with focus concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/vinpocetine-cogn-gen-0140-01",
      "url": "https://doi.org/10.1234/vinpocetine-cogn-gen-0140-01",
      "citation": "COGN-GEN-0140_01 (2012); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with focus concerns; Outcome: focus; DOI: 10.1234/vinpocetine-cogn-gen-0140-01; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "COGN-GEN-0140_02",
      "year": 2013,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "focus",
      "population": "Adults with focus concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/vinpocetine-cogn-gen-0140-02",
      "url": "https://doi.org/10.1234/vinpocetine-cogn-gen-0140-02",
      "citation": "COGN-GEN-0140_02 (2013); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with focus concerns; Outcome: focus; DOI: 10.1234/vinpocetine-cogn-gen-0140-02; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "COGN-GEN-0140_03",
      "year": 2014,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "focus",
      "population": "Adults with focus concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/vinpocetine-cogn-gen-0140-03",
      "url": "https://doi.org/10.1234/vinpocetine-cogn-gen-0140-03",
      "citation": "COGN-GEN-0140_03 (2014); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with focus concerns; Outcome: focus; DOI: 10.1234/vinpocetine-cogn-gen-0140-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/vinpocetine-cogn-gen-0140-01",
      "study_ids": [
        "COGN-GEN-0140_01"
      ],
      "primary_study_id": "COGN-GEN-0140_01",
      "url": "https://doi.org/10.1234/vinpocetine-cogn-gen-0140-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/vinpocetine-cogn-gen-0140-02",
      "study_ids": [
        "COGN-GEN-0140_02"
      ],
      "primary_study_id": "COGN-GEN-0140_02",
      "url": "https://doi.org/10.1234/vinpocetine-cogn-gen-0140-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/vinpocetine-cogn-gen-0140-03",
      "study_ids": [
        "COGN-GEN-0140_03"
      ],
      "primary_study_id": "COGN-GEN-0140_03",
      "url": "https://doi.org/10.1234/vinpocetine-cogn-gen-0140-03"
    }
  ],
  "manifest_hash": "sha256:fac890db394d026438359d4fab7f4480c5f3c5fda21f4458a025437f9541b8d5"
}
